Kornimate/medical-research-clean huggingface dataset:
effectiveness of acetazolamide for reversal of metabolic alkalosis in mechanically ventilated chronic obstructive pulmonary disease patients

Conditions: Decompensated Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to determine whether acetazolamide are effective to reduce the length of mechanical ventilation in decompensated chronic obstructive pulmonary disease (copd) patients developing pure or mixed metabolic alkalosis.

the purpose of this study is to determine whether acetazolamide is effective to reduce the length of mechanical ventilation in decompensated copd patients developing pure or mixed metabolic alkalosis.

Eligibility criteria:
inclusion criteria: * decompensated copd on invasive mechanical ventilation less than 24 hours
neuromodulation in patients with hamstring shortening

Conditions: Hamstring Contractures

Summary: the flexibility of the hamstrings is a very important component both for general health and when exercising. the lack of hamstring flexibility has been related to the increase in the likelihood of suffering a large number of musculoskeletal pathologies, due to the possibility of causing important muscle imbalances, which include lumbar spine pathologies, such as disc hernias or spondyloarthrosis. in addition, the decrease in the flexibility of the hamstring musculature is also related to the increased likelihood of suffering muscle strains, patellar tendon tendinopathies, femoropatellar syndrome and decreased lumbopelvic rhythm. clinically, an invasive technique has appeared, known as ultrasound-guided percutaneous neuromodulation (pnm). this minimally invasive intervention consists in the application of a percutaneous electrical stimulation (pes) through an acupuncture needle-like electrode that is placed in close proximity to the nerve or motor point of the muscle with ultrasound guidance. at the clinical level, the pes is always used with the therapeutic aim of relieving chronic pain and neuropathic pain. similarly, in sports, pes is used with the aim of improving muscular activity. therefore, according to the characteristics and the therapeutic benefits of this technique, further research is needed to discover multiple clinical indications. the aim of this study was to examine the effects on flexibility and strength of an ultrasound-guided percutaneous neuromodulation intervention in patients with shortening of the hamstring muscles.


Eligibility criteria:
inclusion criteria: * over 18 years * to practice some sports activity 2 or more times a week * get less than 70º in pke (passive knee extension) with hip 90º exclusion criteria: * any previous surgery or acute trauma in the back or lower extremity. * pain at the time of performing the assessment tests * belonephobia * anticoagulant consumption * pregnancy * hemorrhagic disorders * immunosuppression * inability to understand or carry out evaluations
ultrasound lipolysis versus cryolipolysis on lipid profile levels in centrally obese middle aged men

Conditions: Ultrasound Lipolysis; Cryolipolysis; Lipid Profile; Central Obesity

Summary: the study compares the effects of ultrasound lipolysis and cryo lipolysis on cholesterol, triglyceride, high density lipoprotein, low density lipoprotein, body mass index, skin thickness, waist circumference, and waist hip ratio in centrally obese middle aged men. it also investigates the impact of ultrasound lipolysis on skin thickness, waist circumference, and waist hip ratio.

obesity has become a key risk factor for the development of cardiovascular diseases and dyslipidemia. overweight and abdominal obesity has increased in men more than in women. for young individuals, intra-abdominal fat is the important component of the body fat for six of the eight metabolic risk factors. intra-abdominal fat might contribute to that most patients with acute myocardial infarction at a young age are men. abdominal lipolysis by ultra sonic is a safe and efficacious method and can effectively decrease waist circumference, waist hip ratio and blood cholesterol. adding cryolipolysis to a low-calorie diet is protocol from other methods to improve the body profile, in form of body mass index, waist-to-hip ratio, as well subcutaneous fat tissues thickness, but also leads to improvement in lipid profile and liver enzymes

Eligibility criteria:
inclusion criteria: 1. obese men with middle age range will be 40-60 years. 2. obese men with central obesity. 3. body mass index (bmi) greater than 30 kg \\m2. 4. waist circumference will be \>94 cm. 5. waist to hip ratio more than 0.9 exclusion criteria: 1. chronic respiratory disorders and cardiovascular problems. 2. diabetic patients. 3. presence of skin diseases in abdominal regions that prevent the use of ultra sound or cryolipolysis therapy. 4. men with kidney or liver diseases. 5. tumor diseases 6. lesions of higher center leading to obesity. 7. history of active or chronic infectious, autoimmune disease. 8. history of abdominal surgeries.
a study of endobiliary radiofrequency ablation in malignant biliary obstructions

Conditions: Biliary Stricture

Summary: the purpose of this study is to assess the impact of temperature-sensitive radiofrequency ablation (rfa) immediately before biliary stent placement on duration of biliary stent patency and re-intervention free survival. this is a research study meant to collect information to help other patients with malignant biliary strictures in the future.


Eligibility criteria:
inclusion criteria: * malignant biliary stricture * participants have or will have a biopsy-confirmed pancreaticobiliary or ampullary malignancy that have agreed to undergo radiofrequency ablation (rfa) with placement of biliary stents * patients with life expectancy greater than 3 months * able to provide consent exclusion criteria: * patients who are pregnant * patients with cirrhosis * patients with significant liver metastasis \&gt;30% on radiologic imaging suggestive of poor liver function that will not improve despite endoscopic drainage. * patients who have undergone prior biliary decompression stents or percutaneous drainage that cannot be removed at time of ercp and thus preclude effective rfa * patients with altered anatomy unable to undergo conventional ercp (i.e., history of roux-en-y gastric bypass)

Keywords: bile duct obstruction biliary stent temperature-sensitive radiofrequency ablation (rfa)
paliperidone extended release in schizophrenia participants with duration of illness less than 10 years

Conditions: Schizophrenia

Summary: the purpose of this study is to evaluate the effectiveness and safety of paliperidone extended release (er) in symptomatic participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) who were receiving treatment with any oral (having to do with the mouth) antipsychotic medication and who needed to be switched to paliperidone er from the current oral antipsychotic therapy due to insufficient efficacy or due to side effects.

this is an open-label (all people know the identity of the intervention), multi-centric (conducted in more than one center) and non-comparative study of paliperidone er in participants with schizophrenia who have a previous history of bad adherence to the antipsychotic treatment because of insufficient efficacy and side-effects. all the eligible participants will receive a dose of paliperidone er in range of 3 to 12 milligram (mg) orally (taken by mouth; to be swallowed) once daily for 13 weeks. efficacy and safety will primarily be evaluated by positive and negative syndromes scale (panss) and extrapyramidal symptom rating scale (esrs), respectively. participants' safety will be monitored throughout the study.

Eligibility criteria:
inclusion criteria: * participants meet the diagnostic and statistical manual of mental disorders fourth edition (dsm-iv) criteria for schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) * positive and negative syndrome scale (panss) total score at baseline of greater than equal to 70 and less than equal to 100 * participants who need to be switched from the current oral antipsychotic therapy because of lack of efficacy or side effects * participants followed as outpatients * female participants must be postmenopausal for at least 1 year, surgically sterile or, if sexually active, be practicing an effective method of birth control and female participants of childbearing potential must also have a negative urine pregnancy test at baseline exclusion criteria: * acute psychotic relapse that requires hospitalization and first antipsychotic treatment ever * participants who had received clozapine during the previous 3 months * history or current symptoms of tardive dyskinesia (twitching or jerking movements that you cannot control in your face, tongue, or other parts of your body) and neuroleptic malignant syndrome (high fever, rigid muscles, shaking, confusion, sweating more than usual, increased heart rate or blood pressure, or muscle pain or weakness) * pregnant or breast-feeding female * participated in an investigational drug trial in the previous 30 days

Keywords: schizophrenia paliperidone
study of motexafin gadolinium and docetaxel for advanced cancer

Conditions: Breast Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Lung Neoplasms; Gastrointestinal Neoplasms

Summary: the primary purpose of this study is to evaluate the safety, side effects, and dosage for motexafin gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers. secondly, tumor response to the combined treatment, drug levels in the body, and drug interactions will be evaluated.


Eligibility criteria:
inclusion criteria: * at least 18 years old * metastatic, or unresectable solid tumors from breast, head, and neck, gastrointestinal, genitourinary, lung, or ovarian cancer or recurrent glioblastoma multiforme * ecog performance status score either 0, 1, or 2 * willing and able to provide written informed consent exclusion criteria: * greater than two prior cytotoxic regimens * laboratory values showing adequate function of bone marrow, liver, and kidneys * uncontrolled hypertension * known sensitivity to or intolerable adverse effects from taxanes (eg. paclitaxel, docetaxel) or polysorbate 80

Keywords: lung cancer breast cancer prostate cancer ovarian cancer head and neck cancer gastrointestinal cancer metastatic cancer advanced cancer genitourinary cancer glioblastoma multiforme recurrent cancer colon cancer gastric cancer stomach cancer pancreatic cancer esophageal cancer throat cancer bladder cancer kidney cancer renal cancer cervical cancer endometrial cancer colorectal cancer
tomus-trial of mid-urethral slings

Conditions: Urinary Incontinence

Summary: the primary aim of this clinical trial is to compare treatment success for two minimally invasive surgical procedures to treat stress urinary incontinence in women. these procedures are called mid-urethral slings. the secondary aims of the trial are to compare other outcomes for the two surgical procedures, including quality of life, sexual function, satisfaction with treatment outcomes, complications, and the need for other treatments(s) after surgery. follow-up will be a minimum of two years.


Eligibility criteria:
inclusion criteria: * female * stress urinary incontinence (sui) as evidenced by all of the following: * self-reported stress-type urinary incontinence symptoms, of duration ≥ 3 months * medical, epidemiological and social aspects of aging (mesa) stress symptom score (percent of total possible stress score) greater than mesa urge symptom score (percent of total possible urge score) * observation of leakage by provocative stress test at a bladder volume ≤ 300ml * bladder capacity ≥ 200ml by stress test * post-void residual (pvr) ≤ 100cc with pelvic organ prolapse (pop) stage i or lower. if pop is stage ii-iv, pvr \>100cc but ≤ 500cc is allowed * eligible for both retropubic and transobturator procedures * no medical contraindications, e.g., current urinary tract infection (uti), history of pelvic irradiation, history of lower urinary tract cancer * american society of anesthesiologists (asa) class i, ii, or iii * no current intermittent catheterization * available for 24-months of follow-up and able to complete study assessments, per clinician judgment * signed consent form exclusion criteria: * age \<21 years * non-ambulatory (ambulatory with assistive devices does not exclude the patient) * pregnancy by self-report or positive pregnancy test, or self-reported intention to ever become pregnant * current chemotherapy or current or history of pelvic radiation therapy * systemic disease known to affect bladder function (i.e., parkinson's disease, multiple sclerosis, spina bifida, spinal cord injury or trauma) * urethral diverticulum, current or previous (i.e. repaired) * prior augmentation cystoplasty or artificial sphincter * implanted nerve stimulators for urinary symptoms * history of synthetic sling for stress urinary incontinence * \<12 months post-partum * laparoscopic or open pelvic surgery \<3 months\* * current evaluation or treatment for chronic pelvic pain (painful bladder syndrome) * participation in another treatment intervention trial that might influence the results of this trial * need for concomitant surgery requiring an abdominal incision, use of graft material in the anterior compartment, or any use of synthetic graft material * enrollment in other urinary incontinence trials including sister/e-sister or be-dri/e-be-dri

Keywords: urinary incontinence, stress surgery
study comparing doses of an experimental glucocorticoid compound to prednisone and placebo in rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to compare the safety and efficacy of multiple doses of pf-04171327, an experimental glucocorticoid drug, to prednisone at 5 mg or 10 mg and placebo in the treatment of rheumatoid arthritis. all subjects will also be receiving background treatment of methotrexate for their rheumatoid arthritis. study medication will be given for eight weeks followed by a 4 week period during which the dose of study medication will be gradually reduced. the efficacy of the study medications will be determined by assessing severity of the rheumatoid arthritis during the study and safety will be determined by adverse event reporting, laboratory tests and biomarker analysis.


Eligibility criteria:
inclusion criteria: * subjects must have documented rheumatoid arthritis with a duration of at least 3 months as determined by the investigator using standardly accepted criteria, must have been receiving methotrexate for at least 3 months to treat their rheumatoid arthritis, and must be free of any signs or symptoms of infection. exclusion criteria: * subjects cannot enter the study if they have recently received treatment with certain medications which might interfere with study medications; * subjects cannot enter if they have abnormalities in certain blood tests, history of cancer, recent bone fracture or other significant conditions.

Keywords: treatment of rheumatoid arthritis treatment of ra patients on methotrexate for rheumatoid arthritis prednisone for rheumatoid arthritis
antiplatelet effects in stroke-patients

Conditions: Ischemic Stroke

Summary: many patients suffer from acute and chronic pain. the incidence of chronic pain correlates with increased age. most of patients rely on analgesic medication to control the pain. dipyrone is an extensively used drug in western and eastern europe as well as central and south america, largely due to its favorable analgesic and antipyretic effects in conjunction with a low incidence of gastrointestinal complications when compared to other non-steroidal anti-inflammatory drugs (nsaids). aspirin is the backbone of antiplatelet therapy in patients after ischemic stroke. however, it is known that there are substantial inter-individual response variabilities to antiplatelet medication. furthermore, patients with impaired response to aspirin have a significant higher risk of recurrent cerebrovascular events. the investigators have recently shown that co-medication with aspirin and dipyrone in patients with coronary artery disease lead to insufficient antiplatelet effects of aspirin. the incidence of chronic pain is very high in patients with ischemic stroke. therefore, in this study the investigators aim to examine, if co-medication of aspirin and dipyrone interaction also occurs in patients after ischemic stroke.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * patients with ischemic stroke and ass-medication (80-320 mg/day) with/without analgesic comedication exclusion criteria: * reanimation * cardiogenic shock

Keywords: ischemic stroke antiplatelet effects aspirin metamizole dipyrone
the marker expression of corneal surface from penetrating keratopathy after collagenase a assisted comet case series

Conditions: Cornea

Summary: in order to examine the cells of the corneal epithelium in the patients who receive corneal transplantation after collagenase a assisted cultivated oral mucosa epithelium transplant (ca-comet), we analyzed the specimens from penetrating keratoplasty with immunochemical staining.

limbal insufficiency may cause persistent corneal erosion, turbidity, and even infection and blindness, leading to major eye damage. in patients with limbal stem cell insufficiency, due to the defect of the limbal stem cells, the new epidermal cells cannot be produced, and without the limbus as a barrier, the cells near the conjunctiva will move toward the center of the cornea, result in replacing the corneal cells and causing corneal conjunctivalization. in recent years, many surgical methods for treating corneal stem cell defects include amniotic membrane transplantation, autologous limbal cell transplantation, and allogeneic limbal cell transplantation. however, in patients with bilateral total limbal insufficiency, there are no autologous limbal cells in the contralateral eye, and allografts may also have rejection and infection. cultured oral mucosa epithelium transplant is a method for treating bilateral full-limbal cell defects. the patient's own oral mucosal cells are cultured in the laboratory, and the cultured epithelium is transplanted to the patient's limbus. in the experiment, mouse cells are used as a feeder cell and transplanted to the human body, which is prone to potential problems such as rejection or infection. in order to resolve these problems, our laboratory modified the process of separating the limbal stem cells. by replacing the dispase ii/trypsin-edta with collagenase a, there were no needs to use a feeder cell. this experiment has been successfully completed under the national plan. in this study, we want to investigate the cells on the ocular surface form the four patients who underwent corneal transplantation after receiving ca-comet. dr.kuan-ting kuo, a pathologist in ntuh, will assist us in the staining of the specimens of the cornea from four patients who underwent corneal transplantation after receiving ca-comet. the specimens of the four patients will be stained (immunohistochemistry) with markers of the cornea and conjunctival cells (k3, k4, k12, k13, k19, muc5, p63).

Eligibility criteria:
inclusion criteria: * the patients who underwent corneal transplantation after receiving ca-comet in five years. exclusion criteria: * the patients who never underwent corneal transplantation after receiving ca-comet.
the clinical application and popularization of portable home noninvasive ventilator

Conditions: Pulmonary Disease, Chronic Obstructive; Hypercapnic Respiratory Failure

Summary: the subjects of this study are the chronic obstructive pulmonary disease (copd) patients with chronic ii respiratory failure. the participants will be divided into two groups: the portable home noninvasive ventilator treatment group and the routine home oxygen inhalation treatment group. all subjects will be given a stable copd regimen and conventional oxygen therapy ,but the portable home noninvasive ventilator treatment group will need to wear a portable non-invasive ventilator. objective evaluation indexes were established during the routine treatment, and two groups of subjects will be followed up for one year. finally, the clinical data of all subjects will be analyzed，and then the practicability of portable wearable household noninvasive ventilator will be verified.the researchers will also build a remote breathing data-monitoring platform based on mobile internet,and a community home demonstration application point.


Eligibility criteria:
inclusion criteria: * 40 years old \< age \< 80 years old * copd diagnosis was made according to gold guidelines * the subjects with chronic type ii respiratory failure * the subjects with structural lung disease * the subjects signed informed consent. exclusion criteria: * the subjects suffering from copd acute exacerbation * the subjects currently participating in other related products * the subjects with organ dysfunction because of liver,kidney, hematopoietic system and serious metabolic disease endocrine system * the subjects with poor compliance * the subjects refused to sign the informed consent

Keywords: pulmonary disease, chronic obstructive respiratory insufficiency oxygen inhalation therapy noninvasive ventilation
prognostic value of pediatric gcs-pupil score in pediatric patients with traumatic brain injury

Conditions: Brain Injuries, Traumatic

Summary: there are studies reporting that the survival rate in pediatric patients with abnormal pupillary response is 23% and that pupillary response is effective on mortality and patient outcomes. studies in the literature examining the effect of pupillary response on mortality and outcome in pediatric patients with traumatic brain injury reported that bilaterally dilated pupils were associated with a higher mortality rate. considering the literature results, we believe that obtaining the gcs-pupil score by combining gcs and pupillary reaction in pediatric patients with traumatic brain injury will be effective in predicting patient outcomes.

obtaining a gcs-pupil score using the total gcs score: 0 points are given for pupillary reaction if both pupils react to light, 1 point if one pupil does not react to light, and 2 points if both pupils do not react to light. total gcs-p score is calculated by the formula of eye response + verbal response + motor response - pupil reaction and scores between 1-15. in the study, the worst gcs and current pupillary light reaction score in the first 24 hours will be evaluated.

Eligibility criteria:
inclusion criteria: * be under the age of 18, * not having mental and motor developmental retardation, * having had a traumatic brain injury, * alive at admission and followed up for at least 24 hours exclusion criteria: * eye trauma or severe facial trauma that will affect the assessment, * those under deep sedation, * those who have been administered drugs (atropine and mydriatic) that will affect the pupillary response.

Keywords: brain traumatic gcs-pupil score pediatric